ZGN-1061
Modify Date: 2025-09-12 17:14:13
ZGN-1061 structure
|
Common Name | ZGN-1061 | ||
|---|---|---|---|---|
| CAS Number | 2082752-83-6 | Molecular Weight | 478.63 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H42N2O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ZGN-1061ZGN-1061 (Aclimostat) is a novel potent, selective Methionine aminopeptidase 2 (MetAP2) inhibitor being investigated for treatment of diabetes and obesity; reduces body weight in diet-induced obese (DIO) insulin-resistant mice, also produced improvements in metabolic parameters, including plasma glucose and insulin, and, in HepG2 cells, initiated gene changes similar to beloranib; does not increase coagulation markers in dogs and ZGN-1061 had a greatly improved safety profile in rats relative to beloranib. Diabetes Phase 2 Clinical |
| Name | ZGN-1061 |
|---|
| Description | ZGN-1061 (Aclimostat) is a novel potent, selective Methionine aminopeptidase 2 (MetAP2) inhibitor being investigated for treatment of diabetes and obesity; reduces body weight in diet-induced obese (DIO) insulin-resistant mice, also produced improvements in metabolic parameters, including plasma glucose and insulin, and, in HepG2 cells, initiated gene changes similar to beloranib; does not increase coagulation markers in dogs and ZGN-1061 had a greatly improved safety profile in rats relative to beloranib. Diabetes Phase 2 Clinical |
|---|---|
| References | References 1. Burkey BF, et al. J Pharmacol Exp Ther. 2018 Feb 28. pii: jpet.117.246272. View Related Products by Target Aminopeptidase Diabetes |
| Molecular Formula | C26H42N2O6 |
|---|---|
| Molecular Weight | 478.63 |
| InChIKey | QJWJPMLDQYEPPW-AUKZVGPFSA-N |
| SMILES | COC1C(OC(=O)N2CC(CCN3CCOCC3)C2)CCC2(CO2)C1C1(C)OC1CC=C(C)C |